Epratuzumab Biosimilar - Research Grade

Human

CD22

>1mg/ml

Human IgG1 Kappa

CHO Cells

Anti-Mouse CD22 (Cy34.1) In Vivo Antibody - Low Endotoxin (ICH1181), Anti-Mouse CD22 (MB22-11) In Vivo Antibody - Low Endotoxin (ICH1216), Pinatuzumab Biosimilar - Research Grade (ICH5093), Inotuzumab Biosimilar - Research Grade (ICH5247), Bectumomab Biosimilar - Research Grade (ICH5379), Mozistobart Biosimilar - Research Grade (ICH5693), Suciraslimab Biosimilar - Research Grade (ICH5884)

https://www.imgt.org/mAb-DB/

ICH3002

P20273

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of epratuzumab, a humanized IgG1 kappa monoclonal antibody directed against human CD22 (Siglec-2). It is supplied for research use only and is not the clinical drug, nor is it intended for human or veterinary use. Built around the CD22 target, the analog reproduces the antigen-binding specificity of the originator, making it a convenient, well-defined reagent for laboratory investigation of CD22 biology and of anti-CD22 antibody behavior. Typical research applications include use as a binding and specificity control, a benchmark or reference antibody in assay development, a positive control in B-cell characterization, and a building block for antibody-drug conjugate (ADC) and effector-function studies. It is produced at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options), and is available in bulk milligram-to-gram quantities and in-vivo-standard preparations. The consistent, characterized format supports reproducible comparisons across experiments and lots without the constraints or cost of sourcing clinical material. CD22 (Siglec-2; UniProt P20273) is a type I transmembrane sialic-acid-binding immunoglobulin-like lectin expressed almost exclusively on B lymphocytes. It appears on the surface during B-cell maturation, is present on mature IgM+/IgD+ B cells, and is generally lost upon differentiation to plasma cells. Its extracellular region contains seven immunoglobulin-like domains; the membrane-distal domain recognizes alpha-2,6-linked sialic acids, mediating homotypic and heterotypic cell interactions. The cytoplasmic tail carries immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that, upon phosphorylation, recruit the phosphatase SHP-1 to dampen B-cell receptor signaling, positioning CD22 as a key inhibitory co-receptor that sets B-cell activation thresholds and supports peripheral tolerance. CD22 also undergoes rapid internalization on antibody engagement. Its restricted B-lineage expression and efficient endocytosis make it an attractive target for antibody-based and conjugate approaches in B-cell malignancies and autoimmunity.

CAT-8015, GCR-8015, HA22, (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14

Detects human CD22

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Epratuzumab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Epratuzumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Epratuzumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Epratuzumab that binds CD22.